Metastatic castration-sensitive prostate cancer – pfizer

Talazoparib is a potent, orally bioavailable, small molecule that is in development for the treatment of a variety of human cancers. In previous studies the combination of talazoparib and anti-PD-L1 antibody significantly reduced tumor growth and improved survival.
Revive Research Institute is conducting a research on Talazoparib to determine its efficacy in treatment of prostate cancer.
The investigational treatment is free for the duration of the clinical trial and insurance is not required.
Participation Criteria:

  • Be > 18 years of age.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell or signet cell features
  • Willing to provide tumor tissue when available (de novo or archived) for retrospective molecular profiling analysis.
  • Additional Criteria may apply.
Enroll in Study

Breast Cancer

Join Us In Our Search For A Breast Cancer-free Tomorrow

People with breast cancer need the support, care, and information, no matter what stage of illness they may be in, to make the right choices about their treatment. With breast cancer being the most common type of cancer in the world, there is a need to find novel and effective therapy options to reduce the pain and the suffering that comes with it.
The Revive Research Institute is conducting a clinical research trial to assess a new therapy for ovarian suppression in the treatment of breast cancer. This prospective treatment could be a scientific breakthrough in the way we treat breast cancers.
Let’s bring hope to people around the world suffering from breast cancer. Help us revive breast cancer treatments and make the world a pain-free and hopeful place.

Participation Criteria:

  • Be between the age of 18 to 55.
  • Be diagnosed with Stage I, II, or III breast cancer.
  • Additional Criteria may apply.

Our group of LICENSED and CERTIFIED oncologists will be keeping track of your progress and will provide you with the support and information you deserve throughout the study.
Don’t lose hope, let’s beat breast cancer!

Enroll in Study

Relapsed/Refractory Follicular Lymphoma

“Help Us Make Your NHL Journey as Smooth & Pain-free As Possible”

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL), representing 20% to 30% of all of the other types. Relapse of FL within 24 months of chemoimmunotherapy is seen quite commonly in patients. We strive to bring a therapy to treat patients with relapsed lymphoma. Revive Research Institute is taking this challenge utilizing new medical technologies and improved treatment modalities to treat relapsed cases of lymphoma. Our research will bring hope to many lives play a role in making the road ahead of you as comfortable and easy as possible.

Participation criteria:        

  • Males or females are ≥18 years of age.
  • Histologically confirmed follicular lymphoma.
  • Comply with study procedures.
  • Additional criteria may apply.

Revive Research Institute is part of your journey with NHL. Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial.

Enroll in Study

Indolent Non-Hodgkin’s Lymphoma

“Relapsed Indolent Non- Hodgkins Lymphoma (NHL)-MEI Pharma”

Therapeutic options for previously untreated FL and MZL include single agent antiCD20 immunotherapy. For patients with relapsed disease, a similar immunochemotherapy approach, utilizing a chemotherapy regimen not previously administered, can be used.

Active agents with different mechanisms of action other than cytotoxic chemotherapy are needed for patients with relapsed indolent Non-Hodgkin’s Lymphoma.

Revive Research Institute is conducting a clinical research trial to find an effective treatment option for patients with relapsed indolent Non-Hodgkin’s Lymphoma.

The investigational treatment is free for the duration of the clinical trial and insurance is not required.

Participation Criteria

  • Be ≥ 18 years of age.
  • Have a confirmed diagnosis of CD20 positive indolent Non-Hodgkin’s Lymphoma.
  •  Additional Criteria may apply.
Enroll in Study

EGFRI-induced Acneiform Lesions

“Metastic colorectal cancer patients with EGFR Inhibitor induced acneiform- Lutris”

Over the past decades, a number of types of chemotherapies have been developed and approved for treating metastatic colorectal cancer. Among the various types of chemotherapies, epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used both as primary therapy as well as in patients who have failed prior chemotherapies.

Revive research institute is conducting research to find an effective treatment for colorectal cancer.

The investigational treatment is free for the duration of the clinical trial and insurance is not required.

Participation Criteria:

  • Be > 18 years of age.
  • Diagnosed with mCRC.
  • Additional Criteria may apply. 
Enroll in Study

Diffuse Large B-Cell Lymphoma

“BRIDGING THE GAP BETWEEN DISCOVERY AND DEVELOPMENT ”

Driven by science and with an aim to advance treatments in oncology, Revive Research Institute is pushing boundaries to deliver new treatment approaches for cancer. We’re developing and investing in scientific capabilities and technologies to help us advance science and achieve the next wave of breakthroughs.
B-Cell Lymphoma is a type of non-Hodgkin lymphoma, which is a cancer of white blood cells that may present with an array of symptoms like fatigue, weight loss, and pain.
Current first-line therapy for cancer treatment is chemotherapy but the development of a more effective first-line treatment option is essential to improve long-term outcomes, particularly in high-risk patients.
Revive Research Institute is conducting a research study to find improved treatment modalities for diffuse large B-cell lymphoma.
Participate in our clinical research trial and join us in innovating the future of oncology medicine.

Participation Criteria:

  • Be 18 years of age or older.
  • Be diagnosed with diffuse large B-cell Lymphoma.
  • Comply with study procedures.
  • Additional criteria may apply.
Enroll in Study

Metastatic Castration-Sensitive Prostate Cancer

“FIGHTING TO KEEP CANCER AWAY”

Prostate cancer is one of the most common types of cancer in men. It affects around 1,275,000 men each year. It can be painful for many men and debilitating, especially as it comes with many risks to the overall health.
Revive research is conducting a clinical trial to investigate a new therapy to treat this malignant disease. We want a future for you that is not limited to prostate cancer.

Participation Criteria:

  • The participant should be 18 years of age or older.
  • Diagnosed with myeloid hematologic Neoplasm.
  • Additional criteria may apply.

Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial.
With some of the brightest minds in science and healthcare, and some of the most caring people and qualified doctors, we want to help you live a fulfilling, long and happy life.

Enroll in Study

Efficacy of Cryotherapy Device in Oral Mucositis

“Come forward and help us giving you a better quality of life ”

Oral mucositis is a common adverse reaction of cancer treatment. It starts 5 -10 days after chemotherapy starts and lasts 7-14 days. Oral mucositis caused by chemotherapy causes the mucosal lining of the mouth to shrink and break down, resulting in ulcers.
Mucositis can make it difficult for a patient to endure chemotherapy, and it can also make it difficult for them to eat well and reduces one’s quality of life. Many medications don’t work efficiently which is why relieving pain with the right treatment is our goal.
Revive Research Institute is conducting a study on a medical device i.e. chemo mouthpiece device that will help patients cope with their discomfort and, as a result, enhance their wellbeing!
Participate in our trial so that we can assist you in living a fulfilling life!

Participation Criteria :

  • Should be aged between 18-80 years.
  • Planning to receive at least 2 cycles of infused somatotopic chemotherapy regimens.
  • Comply with all the study procedures.
  • Additional criteria may apply.

Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial.
Let’s hold out hope for those in need!

Enroll in Study

Metastatic colorectal cancer with EGFRI Induced Acneiform

“Transforming Cancer Treatment ”

Revive Research Institute is dedicated to discovering, researching, and developing treatments that improve the prognosis for cancer patients around the world.

Our cutting-edge research is taking over important breakthrough treatments that will change patients’ lives if they are diagnosed with cancer.

Revive Research Institute is conducting a clinical research trial to find effective treatments for colorectal cancer. Join us in our clinical trials today and change the future of medicine.

Participation Criteria:

  • Be 18 years of age or older.
  • Be diagnosed with colorectal cancer.
  • Comply with study procedures.
  • Additional criteria may apply

Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required.

Enroll in Study

Relapsed/ refractory Myelofibrosis

“Revive will fight for Survival! Because You matter”
There is a significant unmet need for improved therapies in patients with MF who have had a relapse with the treatments available. Most patients are intolerant to the current medications. Revive Research Institute is studying an investigational drug therapy to maximize responsiveness and discover an effective treatment. We at Revive aim to provide Cancer therapy with proven tolerability in phase 1 of the clinical trial. Don’t worry about the cost of treatment. We have it covered for you!
Criteria to Qualify:

  • Adults ≥18 years of age.
  • Must have relapsed or refractory MF.
  • Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician.
  • Additional criteria may apply.
Enroll in Study

Advanced Pancreatic Cancer

“That’s one small step for man, one giant leap for mankind!”
Many cancer pains can be eliminated and all cancer pains can be controlled. With advanced pancreatic cancer, the pain begins in the back and the abdomen before spreading into different parts of the body. Over time, even mild pain can be quite debilitating and handicaps many. It affects sleep, appetite, mood, and indefinitely, the quality of your life.
We at Revive Research Institute believe in the betterment of every life with quality and novel therapy options. We’re here to uncover the latest clinical insights to advance cancer treatments and we need your help to make that one small step that could change the way how we look at cancer treatments.
Participation Criteria:

  • Confirmed diagnosis of pancreatic cancer.
  • Have at least one measurable tumor lesion.
  • Additional Criteria may apply.

Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required.
Equipped with a prospective, therapeutic approach and a determination to improve lives, help us in our discovery for a pain-free and a better tomorrow.

Enroll in Study

COVID 19

“COMBAT COVID WITH REVIVE RESEARCH INSTITUTE!”
Covid-19 is a contagious disease caused by SARS-CoV-2, a new coronavirus variant. It was declared as a global pandemic by WHO in March 2020.Revive Research Institute, as a rising leader in clinical research, is dedicated to finding treatments and enhancing healthcare services.
Our coronavirus clinical research center employs skilled specialists with backgrounds in a wide range of medical conditions to guarantee that you receive the finest COVID-19 therapy available.
Join us in our clinical trial to bring a change.
PARTICIPATION CRITERIA:

  • Be 18 years of age or older.
  • Confirmed and documented diagnosis of Covid-19.
  • Comply with study procedures.
  • Additional criteria may apply.

Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial.
Let’s unite to fight the pandemic together!

Enroll in Study

Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)

“Help create future immune to Non Hodgkin’s Lymphoma”
With a hopeful survival rate of 77 to 86% for patients with non-hodgkin’s lymphoma, our team is continuing to find revolutionary breakthroughs to bring a treatment for patients with relapsed follicular lymphoma (FL). Effectively known immunotherapy is already saving lives, but responses vary from patient to patient and hence require research for new and potent therapies, mainly for cases with relapsed/refractory lymphoma.
Revive Research Institute is working towards efficacious therapy, that too with high potency and harnessing prolonged residence time on target cells. Our goal is to eliminate the need for repeated courses of chemotherapy, associated with cardiac toxicity and myelosuppression.
Join us in our clinical research trial and together let’s celebrate a world immune to Cancer!
Participation Criteria:

  • Male or female subjects ≥18 years of age
  • Histologically confirmed diagnosis of CD20 positive iNHL
  • Comply with study procedures
  • Additional criteria may apply

Our group of licensed and certified physicians will be keeping track of your progress throughout the study and will address any concerns or queries you may have about the research trial.

Enroll in Study